A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma

Cancer Treatment Reviews

Volumn 40, Issue 4, 2014, Pages 533-547

  Funakoshi, Tomohiro ^a   Lee, Chung Han ^b   Hsieh, James J ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Biomarkers; Metastatic renal cell carcinoma; Systematic review; Vascular endothelial growth factor targeted therapy

Indexed keywords

ALPHA INTERFERON RECEPTOR; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON ALPHA RECEPTOR 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; OSTEOPONTIN; PAZOPANIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE B; PROTEIN S6; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

CANCER PROGNOSIS; CANCER SURVIVAL; EVIDENCE BASED MEDICINE; HUMAN; KIDNEY CARCINOMA; MYELOID DENDRITIC CELL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

BIOMARKERS; METASTATIC RENAL CELL CARCINOMA; SYSTEMATIC REVIEW; VASCULAR ENDOTHELIAL GROWTH FACTOR-TARGETED THERAPY;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896726545     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.11.008     Document Type: Review

References (74)

1. Patel P.H., Chadalavada R.S., Chaganti R.S., Motzer R.J. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006, 12(24):7215-7220. [Epub 2006/12/26].
2. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134. Epub 2007/01/12.
3. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2):115-124. [Epub 2007/01/12].
4. Rixe O., Bukowski R.M., Michaelson M.D., Wilding G., Hudes G.R., Bolte O., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007, 8(11):975-984. [Epub 2007/10/26].
5. Hutson T.E., Davis I.D., Machiels J.P., De Souza P.L., Rottey S., Hong B.F., et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010, 28(3):475-480. [Epub 2009/12/17].
6. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370(9605):2103-2111. [Epub 2007/12/25].
7. Schutz F.A., Je Y., Richards C.J., Choueiri T.K. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012, 30(8):871-877. [Epub 2012/02/09].
8. Sivendran S., Liu Z., Portas L.J., Yu M., Hahn N., Sonpavde G., et al. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev 2012, 38(7):919-925. [Epub 2012/06/02].
9. Simon R.M., Paik S., Hayes D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009, 101(21):1446-1452. [Epub 2009/10/10].
10. Hayes D.F., Bast R.C., Desch C.E., Fritsche H., Kemeny N.E., Jessup J.M., et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996, 88(20):1456-1466. [Epub 1996/10/16].
11. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010, 8(5):336-341. [Epub 2010/02/23].
12. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). http://www.eortc.be/recist/documents/RECISTGuidelines.pdf.
13. Rini B.I., Jaeger E., Weinberg V., Sein N., Chew K., Fong K., et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006, 98(4):756-762. [Epub 2006/07/11].
14. Deprimo S.E., Bello C.L., Smeraglia J., Baum C.M., Spinella D., Rini B.I., et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007, 5:32. [Epub 2007/07/04].
15. Choueiri T.K., Vaziri S.A., Jaeger E., Elson P., Wood L., Bhalla I.P., et al. Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008, 180(3):860-865. [discussion 5-6. Epub 2008/07/19].
16. Rini B.I., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., Stadler W.M., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26(22):3743-3748. [Epub 2008/08/02].
17. van Cruijsen H., van der Veldt A.A., Vroling L., Oosterhoff D., Broxterman H.J., Scheper R.J., et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008, 14(18):5884-5892. [Epub 2008/09/17].
18. Kontovinis L.F., Papazisis K.T., Touplikioti P., Andreadis C., Mouratidou D., Kortsaris A.H. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009, 9:82. [Epub 2009/03/17].
19. Jonasch E., Corn P., Pagliaro L.C., Warneke C.L., Johnson M.M., Tamboli P., et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010, 116(1):57-65. [Epub 2009/10/29].
20. Perez-Gracia J.L., Prior C., Guillen-Grima F., Segura V., Gonzalez A., Panizo A., et al. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 2009, 101(11):1876-1883. [Epub 2009/11/12].
21. Tsavachidou-Fenner D., Tannir N., Tamboli P., Liu W., Petillo D., Teh B., et al. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol 2010, 21(8):1599-1606. [Epub 2010/01/22].
22. Porta C., Paglino C., Imarisio I., Ganini C., Sacchi L., Quaglini S., et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 2013, 84(2):115-122. [Epub 2012/11/17].
23. Choueiri T.K., Regan M.M., Rosenberg J.E., Oh W.K., Clement J., Amato A.M., et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010, 106(6):772-778. [Epub 2010/03/17].
24. Paule B., Bastien L., Deslandes E., Cussenot O., Podgorniak M.P., Allory Y., et al. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PloS One 2010, 5(5):e10715. [Epub 2010/05/27].
25. Pena C., Lathia C., Shan M., Escudier B., Bukowski R.M. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 2010, 16(19):4853-4863. [Epub 2010/07/24].
26. Adotevi O., Pere H., Ravel P., Haicheur N., Badoual C., Merillon N., et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010, 33(9):991-998. [Epub 2010/10/16].
27. van der Veldt A.A., Eechoute K., Gelderblom H., Gietema J., Guchelaar H.J., van Erp N.P., et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011, 17(3):620-629. [Epub 2010/11/26].
28. Busse A., Asemissen A., Nonnenmacher A., Ochsenreither S., Fusi A., Braun F., et al. Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-beta1 mRNA expression in peripheral blood mononuclear cells. J Immunother 2011, 34(1):113-119. [Epub 2010/12/15].
29. Gruenwald V., Beutel G., Schuch-Jantsch S., Reuter C., Ivanyi P., Ganser A., et al. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer 2010, 10:695. [Epub 2011/01/05].
30. Furuya N., Kamai T., Shirataki H., Yanai Y., Fukuda T., Mizuno T., et al. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma. Cancer Immunol Immunother 2011, 60(6):793-808. [Epub 2011/02/26].
31. Farace F., Gross-Goupil M., Tournay E., Taylor M., Vimond N., Jacques N., et al. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer 2011, 104(7):1144-1150. [Epub 2011/03/10].
32. Kusuda Y., Miyake H., Behnsawy H.M., Fukuhara T., Inoue T.A., Fujisawa M. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. Urol Oncol 2013, 31(1):42-50. [Epub 2011/03/15].
33. Zurita A.J., Jonasch E., Wang X., Khajavi M., Yan S., Du D.Z., et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012, 23(1):46-52. [Epub 2011/04/06].
34. Terakawa T., Miyake H., Kusuda Y., Fujisawa M. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol 2013, 31(4):493-498. [Epub 2011/04/12].
35. Xu C.F., Bing N.X., Ball H.A., Rajagopalan D., Sternberg C.N., Hutson T.E., et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011, 29(18):2557-2564. [Epub 2011/05/18].
36. Kim J.J., Vaziri S.A., Rini B.I., Elson P., Garcia J.A., Wirka R., et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012, 118(7):1946-1954. [Epub 2011/09/02].
37. Tomita Y., Uemura H., Fujimoto H., Kanayama H.O., Shinohara N., Nakazawa H., et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Eur J Cancer 2011, 47(17):2592-2602. [Epub 2011/09/06].
38. Barrios C.H., Hernandez-Barajas D., Brown M.P., Lee S.H., Fein L., Liu J.H., et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012, 118(5):1252-1259. [Epub 2011/09/08].
39. Garcia-Donas J., Esteban E., Leandro-Garcia L.J., Castellano D.E., del Alba A.G., Climent M.A., et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011, 12(12):1143-1150. [Epub 2011/10/22].
40. Siraj M.A., Pichon C., Radu A., Ghinea N. Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib. J Cell Mol Med 2012, 16(9):2010-2016. [Epub 2011/12/02].
41. Mancuso A., Di Paola E.D., Leone A., Catalano A., Calabro F., Cerbone L., et al. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. BJU Int 2012, 109(2):200-206. [Epub 2012/01/04].
42. de Martino M., Hoetzenecker K., Ankersmit H.J., Roth G.A., Haitel A., Waldert M., et al. Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis. Br J Cancer 2012, 106(5):904-908. [Epub 2012/01/31].
43. Saez M.I., Trigo Pérez J.M., Perez-Rivas L.G., Perez-Villa L., Cid J.I. Hypoxia-inducible factor (HIF) 1α and 2α as predictive markers of outcome to VEGFR tyrosine kinase inhibitors (TKI) in renal cell carcinoma (RCC). J Clin Oncol 2012, 30. [suppl; abstr 4630].
44. DA C., Portella L., Ottaiano A., Rizzo M., Carteni G., Pignata S., et al. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. Curr Cancer Drug Targets 2012, 12(6):69-702. [Epub 2012/04/03].
45. Lambrechts D., Claes B., Delmar P., Reumers J., Mazzone M., Yesilyurt B.T., et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012, 13(7):724-733. [Epub 2012/05/23].
46. Muriel López C., Esteban E., Astudillo A., Pardo P., Berros I.P., Izquierdo M., et al. Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Invest New Drugs 2012, 30(6):2443-2449. [Epub 2012/05/27].
47. Tran H.T., Liu Y., Zurita A.J., Lin Y., Baker-Neblett K.L., Martin A.M., et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012, 13(8):827-837. [Epub 2012/07/05].
48. Choueiri T.K., Cheng S., Qu A.Q., Pastorek J., Atkins M.B., Signoretti S. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol 2012, [Epub 2012/11/13].
49. Porta C., Paglino C., De Amici M., Quaglini S., Sacchi L., Imarisio I., et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 2010, 77(9):809-815. [Epub 2010/02/12].
50. Hegde P.S., Jubb A.M., Chen D., Li N.F., Meng Y.G., Bernaards C., et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 2013, 19(4):929-937. [Epub 2012/11/22].
51. Gigante M., Li G., Ferlay C., Perol D., Blanc E., Paul S., et al. Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy. Anticancer Res 2012, 32(12):5447-5451. [Epub 2012/12/12].
52. Gamez-Pozo A., Anton-Aparicio L.M., Bayona C., Borrega P., Gallegos Sancho M.I., Garcia-Dominguez R., et al. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 2012, 14(12):1144-1152. [Epub 2013/01/12].
53. Feng G., Ye X., Fang F., Pu C., Huang H., Li G. Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. Dis Markers 2013, 34(2):105-111. [Epub 2013/01/18].
54. Beuselinck B., Karadimou A., Lambrechts D., Claes B., Wolter P., Couchy G., et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2013, 108(4):887-900. [Epub 2013/03/07].
55. Beuselinck B., Karadimou A., Lambrechts D., Claes B., Wolter P., Couchy G., et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis. Acta Oncol 2013, DOI: 10.3109/0284186X.2013.770600.
56. Scartozzi M., Bianconi M., Faloppi L., Loretelli C., Bittoni A., Del Prete M., et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer 2013, 108(5):1126-1132. [Epub 2013/03/21].
57. Kobayashi M., Kubo T., Komatsu K., Fujisaki A., Terauchi F., Natsui S., et al. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol 2013, 30(2):556. [Epub 2013/03/30].
58. Garcia-Donas J., Leandro-Garcia L.J., Gonzalez Del Alba A., Morente M., Alemany I., Esteban E., et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol 2013, 24(9):2409-2414. [Epub 2013/06/22].
59. Choueiri T.K., Fay A.P., Gagnon R., Lin Y., Bahamon B., Brown V., et al. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res 2013, 19(18):5218-5226. [Epub 2013/07/25].
60. Xu C.F., Johnson T., Choueiri T.K., Deen K.C., Xue Z., Spraggs C.F., et al. Association of IL8 polymorphisms with overall survival in patients with renal cell carcinoma in COMPARZ (pazopanib versus sunitinib phase III study). J Clin Oncol 2013, 31. [suppl; abstr 4519].
61. Figueroa D.J., Liu Y., Gagnon R.C., Carpenter C., Dar M., Bartlett-Pandite A.N., et al. Correlation of PDL1 tumor expression and outcomes in renal cell carcinoma (RCC) patients (pts) treated with pazopanib (paz). J Clin Oncol 2013, 31. [suppl; abstr 3021].
62. Nixon A.B., Halabi S., Shterev I., Starr M., Brady J.C., Dutcher J.P., et al. Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance). J Clin Oncol 2013, 31. [suppl; abstr 4520].
63. 2 sensing and cancer. Nat Rev Cancer 2008, 8(11):865-873. [Epub 2008/10/17].
64. Aggarwal B.B., Sethi G., Ahn K.S., Sandur S.K., Pandey M.K., Kunnumakkara A.B., et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006, 1091:151-169. [Epub 2007/03/08].
65. Chang S.G., Shin C., Rho S.K., Kim D.K., Kim J.H. Cytokine production in primary histoculture by human normal kidney, renal cell carcinoma and benign renal angiomyolipoma tissues. Anticancer Res 1998, 18(6A):4195-4200. [Epub 1999/01/19].
66. Fitzgerald J.P., Nayak B., Shanmugasundaram K., Friedrichs W., Sudarshan S., Eid A.A., et al. Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8-production. PloS One 2012, 7(1):e30712. [Epub 2012/02/04].
67. Heng D.Y., Xie W., Regan M.M., Warren M.A., Golshayan A.R., Sahi C., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27(34):5794-5799. [Epub 2009/10/15].
68. Heng D.Y., Xie W., Regan M.M., Harshman L.C., Bjarnason G.A., Vaishampayan U.N., et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol 2013, 14(2):141-148. [Epub 2013/01/15].
69. Zhang H.L., Zhu Y., Wang C.F., Yao X.D., Zhang S.L., Dai B., et al. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. Int J Urol 2011, 18(6):422-430. [Epub 2011/04/13].
70. Fujita T., Iwamura M., Ishii D., Tabata K., Matsumoto K., Yoshida K., et al. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol 2012, 19(10):908-913. [Epub 2012/06/08].
71. Yann-Alexandre V., Beuselinck B., Wolter P., Teghom C., Philip D., Karadimou A., et al. Prognostic impact of baseline serum C-reactive protein in metastatic renal cell carcinoma treated with sunitinib. J Clin Oncol 2013, 31. [suppl 6; abstr 425].
72. Hollen C.W., Henthorn J., Koziol J.A., Burstein S.A. Serum interleukin-6 levels in patients with thrombocytosis. Leuk Lymphoma 1992, 8(3):235-241. [Epub 1992/10/01].
73. Blay J.Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992, 52(12):3317-3322. [Epub 1992/06/15].
74. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97(16):1180-1184.